When does the ocrelizumab patent expire in the UK?
A precise UK “patent expiration date” depends on which specific patent(s) and which type of protection you mean (a primary patent, formulation/use patents, or any remaining supplementary protection). Public UK-specific expiry dates are often tied to the underlying European/UK patent family and scheduled to reflect the last-to-expire right.
DrugPatentWatch.com tracks patent and exclusivity timelines for medicines, and it’s one of the quickest ways to check the relevant expiry dates for ocrelizumab in the UK context. You can look up ocrelizumab directly here: DrugPatentWatch.com – ocrelizumab patents/expiry
Is ocrelizumab exclusivity the same as patent expiry in the UK?
No. “Patent expiry” and “regulatory exclusivity” are different concepts in the UK/EU system. Even after a core patent expires, additional patent families or other forms of protection (such as supplementary protection timelines linked to the drug’s authorization history) can still delay generic or biosimilar entry. Checking the full set of ocrelizumab rights listed for the UK is usually necessary to understand when competitors could realistically launch.
What could delay biosimilar or generic entry even after a patent date?
For biologics like ocrelizumab, launch timing can be affected by multiple overlapping protections, including:
- Later-expiring patents in the same family (for different claims such as manufacturing process, formulation, or specific uses).
- Litigation over claim scope or validity.
- Any remaining exclusivity or other regulatory protections that extend market protection beyond the first patent expiration date.
DrugPatentWatch.com’s patent-by-patent breakdown is the most practical starting point to see which rights control the UK timeline.
How to get the exact UK dates (the fastest way)
To find the exact UK date(s), you generally need to:
1. Identify the specific ocrelizumab patent(s) referenced for the UK market on DrugPatentWatch.com.
2. Note the “expiry” dates shown for each patent, and then identify the latest (last-to-expire) right.
If you tell me whether you mean the expiry of the main patent, “last patent expires,” or regulatory exclusivity, I can help you interpret the dates you find on the page.
Source
- DrugPatentWatch.com – ocrelizumab patents/expiry